A novel human IgA monoclonal antibody protects against tuberculosis.

A novel human IgA monoclonal antibody protects against tuberculosis.
复制标题

DOI:
10.4049/jimmunol.1003189
复制
发表时间:
2011-03-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
通讯作者:
Ivanyi J
Ivanyi J
中科院分区:
其他
文献类型:
--
作者:
Balu S;Reljic R;Lewis MJ;Pleass RJ;McIntosh R;van Kooten C;van Egmond M;Challacombe S;Woof JM;Ivanyi J

文献摘要

参考文献

被引文献

相似文献

小鼠实验模型表明,抗体对结核感染的被动免疫治疗具有保护作用。在这项研究中,我们报告了一种新的人类IgA1的性质,它是用从Ab噬菌体文库中选择的单链可变片段克隆(2E9)构建的。纯化后的Ab单体对分枝杆菌α-结晶蛋白Ag和人FcαRI (CD89) IgA受体具有较高的结合亲和力。鼻内接种2E9IgA1和重组小鼠IFN-γ显著抑制了转人CD89基因小鼠的肺部H37Rv感染,但在CD89阴性的同窝对照中没有作用,这表明与CD89的结合是iga赋予的被动保护所必需的。添加到人全血或单核细胞培养物中的2E9IgA1抑制了荧光素酶标记的H37Rv感染,尽管并非对所有接受测试的献血者都有效。在纯化的人单核细胞培养物中,2E9IgA1的抑制作用与人rIFN-γ具有协同作用,但在全血培养物中没有。证明FcαRI (CD89)在人iga介导的保护中的强制性作用,对于理解相关机制以及将这种方法转化为结核病被动免疫治疗的发展具有重要意义。
Abs have been shown to be protective in passive immunotherapy of tuberculous infection using mouse experimental models. In this study, we report on the properties of a novel human IgA1, constructed using a single-chain variable fragment clone (2E9), selected from an Ab phage library. The purified Ab monomer revealed high binding affinities for the mycobacterial α-crystallin Ag and for the human FcαRI (CD89) IgA receptor. Intranasal inoculations with 2E9IgA1 and recombinant mouse IFN-γ significantly inhibited pulmonary H37Rv infection in mice transgenic for human CD89 but not in CD89-negative littermate controls, suggesting that binding to CD89 was necessary for the IgA-imparted passive protection. 2E9IgA1 added to human whole-blood or monocyte cultures inhibited luciferase-tagged H37Rv infection although not for all tested blood donors. Inhibition by 2E9IgA1 was synergistic with human rIFN-γ in cultures of purified human monocytes but not in whole-blood cultures. The demonstration of the mandatory role of FcαRI (CD89) for human IgA-mediated protection is important for understanding of the mechanisms involved and also for translation of this approach toward development of passive immunotherapy of tuberculosis.
DOI: 10.1016/j.imlet.2003.11.018
发表时间: 2004-03-29
期刊: IMMUNOLOGY LETTERS
影响因子: 4.4
作者:
Otten, MA;van Egmond, M
通讯作者: van Egmond, M
DOI: 10.1016/j.ijmm.2008.10.007
发表时间: 2009-08-01
影响因子: 4.1
作者:
Lopez, Yamile;Yero, Daniel;Acosta, Armando
通讯作者: Acosta, Armando
DOI: 10.1016/j.immuni.2004.11.017
发表时间: 2005-01-01
期刊: IMMUNITY
影响因子: 32.4
作者:
Pasquier, B;Launay, P;Monteiro, RC
通讯作者: Monteiro, RC
DOI: 10.1038/nri1704
发表时间: 2005-10-01
影响因子: 100.3
作者:
Nunn, P;Williams, B;Raviglione, M
通讯作者: Raviglione, M
DOI: 10.1038/79494
发表时间: 2000-09-01
影响因子: 46.9
作者:
de Wildt, RMT;Mundy, CR;Tomlinson, IM
通讯作者: Tomlinson, IM